GREAT POINT PARTNERS LLC
13F Reported Value
ⓘ$435.1M
incl. option notional
Equity Holdings
ⓘ$408.3M
Option Notional
ⓘ$26.8M
$23.0M puts / $3.8M calls
Holdings
42
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
GREAT POINT PARTNERS LLC disclosed 42 positions worth $435.1M in its Form 13F-HR for Q1 2026 — $408.3M in common stock plus $26.8M of put/call option positions (reported at underlying notional value, not premium at risk), led by $APGE (Apogee Therapeutics, Inc.) at 7.7% of the equity portfolio, followed by $VOR and $ZURA. During the quarter the fund opened 21 new positions and exited 8 — including a new stake in $IBRX and a full exit from $IRON. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from GREAT POINT PARTNERS LLC’s Form 13F-HR filing with the SEC under CIK 1281446.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$31.5M374,000 sh - —
Quality
$31.2M1,750,000 sh - —
Quality
$25.1M4,215,930 sh - —
Quality
$24.3M1,750,000 sh - 30.0
Quality
$23.0M3,000,800 sh - 10.2
Quality
$22.8M316,453 sh - —
Quality
$21.7M274,363 sh - 9.2
Quality
$18.9M856,061 sh - —
Quality
$16.1M220,000 sh - —
Quality
$13.8M2,500,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Apogee Therapeutics, Inc.$APGE | — | $31.5M | 374,000 |
 Vor Biopharma Inc.$VOR | — | $31.2M | 1,750,000 |
 Zura Bio Ltd$ZURA | — | $25.1M | 4,215,930 |
 Amylyx Pharmaceuticals, Inc.$AMLX | — | $24.3M | 1,750,000 |
 ImmunityBio, Inc.$IBRXPUT | 30.0 | $23.0M | 3,000,800 |
 NEKTAR THERAPEUTICS$NKTR | 10.2 | $22.8M | 316,453 |
 Sol-Gel Technologies Ltd.$SLGL | — | $21.7M | 274,363 |
 ALUMIS INC.$ALMS | 9.2 | $18.9M | 856,061 |
 BRIGHT MINDS BIOSCIENCES INC.$DRUG | — | $16.1M | 220,000 |
 Annexon, Inc.$ANNX | — | $13.8M | 2,500,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of GREAT POINT PARTNERS LLC's 42 positions.
Showing top 10 of 42 holdings.
Sector Allocation
Healthcare
$408.3M
Full Holdings — GREAT POINT PARTNERS LLC (Q1 2026)
All 42 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $APGE | Apogee Therapeutics, Inc. | $31.5M | 7.7% | +0% | — |
| 2 | $VOR | Vor Biopharma Inc. | $31.2M | 7.7% | +28% | — |
| 3 | $ZURA | Zura Bio Ltd | $25.1M | 6.1% | +10% | — |
| 4 | $AMLX | Amylyx Pharmaceuticals, Inc. | $24.3M | 6.0% | +0% | — |
| 5 | $IBRXPUT | ImmunityBio, Inc. | $23.0M | — | NEW | 30 |
| 6 | $NKTR | NEKTAR THERAPEUTICS | $22.8M | 5.6% | +50% | 10.2 |
| 7 | $SLGL | Sol-Gel Technologies Ltd. | $21.7M | 5.3% | NEW | — |
| 8 | $ALMS | ALUMIS INC. | $18.9M | 4.6% | NEW | 9.2 |
| 9 | $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $16.1M | 3.9% | NEW | — |
| 10 | $ANNX | Annexon, Inc. | $13.8M | 3.4% | NEW | — |
| 11 |  $KALV | KalVista Pharmaceuticals, Inc. | $13.6M | 3.3% | -2% | 25.9 |
| 12 |  $IMVT | Immunovant, Inc. | $13.6M | 3.3% | -27% | — |
| 13 |  $JBIO | Jade Biosciences, Inc. | $13.6M | 3.3% | +20% | — |
| 14 |  $CTNM | Contineum Therapeutics, Inc. | $10.5M | 2.6% | +0% | — |
| 15 |  $ZBIO | Zenas BioPharma, Inc. | $10.2M | 2.5% | NEW | 14.4 |
| 16 |  $NGNE | Neurogene Inc. | $10.1M | 2.5% | +43% | — |
| 17 |  $MLTX | MoonLake Immunotherapeutics | $9.3M | 2.3% | NEW | — |
| 18 |  $CLYM | Climb Bio, Inc. | $9.1M | 2.2% | +36% | — |
| 19 |  $ORKA | Oruka Therapeutics, Inc. | $9.0M | 2.2% | +0% | — |
| 20 |  $EPRX | EUPRAXIA PHARMACEUTICALS INC. | $8.7M | 2.1% | +0% | — |
| 21 |  $VERA | Vera Therapeutics, Inc. | $8.0M | 2.0% | NEW | — |
| 22 |  $EVMN | Evommune, Inc. | $7.5M | 1.8% | +0% | — |
| 23 |  $LBRX | LB PHARMACEUTICALS INC | $7.4M | 1.8% | NEW | — |
| 24 |  $CMPX | Compass Therapeutics, Inc. | $7.1M | 1.8% | NEW | — |
| 25 |  $SCYX | SCYNEXIS INC | $6.9M | 1.7% | NEW | — |
| 26 |  $PALI | PALISADE BIO, INC. | $6.0M | 1.5% | NEW | — |
| 27 |  $CNTX | Context Therapeutics Inc. | $5.9M | 1.4% | -52% | — |
| 28 |  $RLMD | RELMADA THERAPEUTICS, INC. | $5.9M | 1.4% | NEW | — |
| 29 |  $SLN | Silence Therapeutics plc | $5.4M | 1.3% | +26% | — |
| 30 |  $UNCY | Unicycive Therapeutics, Inc. | $5.2M | 1.3% | +0% | — |
| 31 |  $TENX | TENAX THERAPEUTICS, INC. | $5.2M | 1.3% | NEW | — |
| 32 |  $PMN | ProMIS Neurosciences Inc. | $4.7M | 1.2% | NEW | — |
| 33 |  $CGEM | Cullinan Therapeutics, Inc. | $4.3M | 1.0% | -53% | — |
| 34 |  $IMMX | Immix Biopharma, Inc. | $3.2M | 0.8% | NEW | — |
| 35 |  $RZLT | Rezolute, Inc. | $2.9M | 0.7% | +0% | — |
| 36 |  $PHVS | Pharvaris N.V. | $2.3M | 0.6% | +0% | — |
| 37 |  $HUMA | Humacyte, Inc. | $2.3M | 0.6% | NEW | 5 |
| 38 |  $GALTCALL | GALECTIN THERAPEUTICS INC | $2.2M | — | NEW | — |
| 39 |  $AVTX | Avalo Therapeutics, Inc. | $1.9M | 0.5% | +0% | 4.6 |
| 40 |  $ALKS | Alkermes plc. | $1.8M | 0.4% | NEW | — |
| 41 |  $AVXLCALL | ANAVEX LIFE SCIENCES CORP. | $1.6M | — | NEW | — |
| 42 |  $IRD | Opus Genetics, Inc. | $1.5M | 0.4% | NEW | — |
New Positions (21)
$IBRXPUT ImmunityBio, Inc.$23.0M$SLGL Sol-Gel Technologies Ltd.$21.7M$ALMS ALUMIS INC.$18.9M$DRUG BRIGHT MINDS BIOSCIENCES INC.$16.1M$ANNX Annexon, Inc.$13.8M$ZBIO Zenas BioPharma, Inc.$10.2M$MLTX MoonLake Immunotherapeutics$9.3M$VERA Vera Therapeutics, Inc.$8.0M$LBRX LB PHARMACEUTICALS INC$7.4M$CMPX Compass Therapeutics, Inc.$7.1M$SCYX SCYNEXIS INC$6.9M$PALI PALISADE BIO, INC.$6.0M$RLMD RELMADA THERAPEUTICS, INC.$5.9M$TENX TENAX THERAPEUTICS, INC.$5.2M$PMN ProMIS Neurosciences Inc.$4.7M
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for GREAT POINT PARTNERS LLC including:
Track GREAT POINT PARTNERS LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for GREAT POINT PARTNERS LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: GREAT POINT PARTNERS LLC
13F Pro is an AI hedge fund tracker and stock research platform. For GREAT POINT PARTNERS LLC (SEC CIK: 1281446), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in GREAT POINT PARTNERS LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.